Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.22.1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents [note 5] $ 36,337 $ 43,022
Grant receivable   153
Prepaid expenses and other assets 1,355 1,419
Total current assets 37,692 44,594
Right-of-use assets [note 8] 49 64
Other assets and restricted cash [note 5] 253 183
License agreement [note 3 and 4] 1,586 1,641
Goodwill [note 4] 1,034 1,034
Total assets 40,614 47,516
Current liabilities:    
Accounts payable 418 841
Accrued liabilities other 648 348
Accrued clinical liabilities 2,222 1,352
Accrued compensation 663 1,940
Current portion of long-term obligations [note 8] 59 69
Total current liabilities 4,010 4,550
Convertible debt [note 6] 15,171 14,920
Long-term obligations [note 8]   4
Total liabilities 19,181 19,474
Commitments and contingencies [note 8]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 9,473,577 issued and outstanding at March 31, 2022 and 9,453,542 issued and outstanding at December 31, 2021 79 79
Additional paid-in capital 122,509 121,545
Accumulated deficit (101,159) (93,586)
Accumulated other comprehensive income 4 4
Total stockholders' equity 21,433 28,042
Total liabilities and stockholders' equity 40,614 47,516
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value